This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/20/2026
Jones et al (2019)2 conducted a subset analysis to compare the efficacy and safety of YONDELIS when administered in the inpatient vs outpatient setting during the phase 3 pivotal study (SAR-3007)1.
| Adverse Event, n (%) | Inpatients (n=100) | Outpatients (n=277) |
|---|---|---|
| Nausea | 73 (73) | 212 (77) |
| Fatigue | 63 (63) | 199 (72) |
| Anemia | 58 (58) | 99 (36) |
| Alanine aminotransferase increased | 54 (54) | 133 (48) |
| Vomiting | 47 (47) | 126 (46) |
| Aspartate aminotransferase increased | 43 (43) | 99 (36) |
| Decreased appetite | 38 (38) | 103 (37) |
| Neutropenia | 37 (37) | 81 (29) |
| Constipation | 34 (34) | 107 (39) |
| Diarrhea | 34 (34) | 97 (35) |
| Peripheral edema | 33 (33) | 75 (27) |
| Cough | 30 (30) | 56 (20) |
| Headache | 29 (29) | 66 (24) |
| Neutrophil count decreased | 28 (28) | 68 (25) |
| Dyspnea | 28 (28) | 66 (24) |
| Blood alkaline phosphatase increased | 28 (28) | 59 (21) |
| Pyrexia | 25 (25) | 48 (17) |
| Hypokalemia | 25 (25) | 28 (10) |
| White blood cell count decreased | 24 (24) | 73 (26) |
| Thrombocytopenia | 24 (24) | 49 (18) |
| Platelet count decreased | 22 (22) | 41 (15) |
| Blood creatinine phosphokinase increased | 20 (20) | 37 (13) |
| Pain in extremity | 20 (20) | 29 (11) |
| Adverse Event, n (%) | Inpatients (n=100) | Outpatients (n=277) |
|---|---|---|
| Alanine aminotransferase increased | 29 (29) | 82 (30) |
| Neutropenia | 27 (27) | 63 (23) |
| Anemia | 26 (26) | 41 (15) |
| Neutrophil count decreased | 23 (23) | 54 (20) |
| White blood cell count decreased | 20 (20) | 55 (20) |
| Aspartate aminotransferase increased | 16 (16) | 41 (5) |
| Platelet count decreased | 15 (15) | 24 (9) |
| Thrombocytopenia | 14 (14) | 25 (9) |
| Leukopenia | 10 (10) | 27 (10) |
| Nausea | 10 (10) | 16 (6) |
| Fatigue | 9 (9) | 23 (8) |
| Vomiting | 8 (8) | 15 (5) |
| Dehydration | 6 (6) | 12 (4) |
| Pulmonary embolism | 6 (6) | 6 (2) |
| Asthenia | 6 (6) | 1 (0.4) |
| Blood creatinine phosphokinase increased | 5 (5) | 17 (6) |
| Febrile neutropenia | 5 (5) | 13 (5) |
| Dyspnea | 5 (5) | 11 (4) |
| Hypokalemia | 5 (5) | 9 (3) |
| Catheter site infection | 5 (5) | 6 (2) |
| Hypoalbuminemia | 5 (5) | 2 (0.7) |
| Adverse Event, n (%) | Inpatients (n=100) | Outpatients (n=277) | ||
|---|---|---|---|---|
| Total | Grade 3 | Total | Grade 3 | |
| Catheter-related complications | 16 (16) | 6 (6) | 42 (15) | 14 (5) |
| Catheter site infection | 5 (5) | 5 (5) | 14 (5) | 6 (2) |
| Catheter site pain | 7 (7) | 0 (0) | 12 (4) | 3 (1) |
| Catheter site inflammation | 1 (1) | 1 (1) | 7 (3) | 0 (0) |
| Infusion site extravasation | 0 (0) | 0 (0) | 5 (2) | 2 (1) |
| Thrombosis in device | 0 (0) | 0 (0) | 5 (2) | 1 (0.4) |
| Soft-tissue necrosis | 0 (0) | 0 (0) | 4 (1) | 4 (1) |
| Catheter site erythema | 1 (1) | 0 (0) | 3 (1) | 0 (0) |
| Catheter site pruritic | 1 (1) | 0 (0) | 3 (1) | 0 (0) |
| Catheter site cellulitis | 1 (1) | 0 (0) | 2 (1) | 0 (0) |
| Catheter-site related reaction | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Device breakage | 0 (0) | 0 (0) | 1 (0.4) | 1 (0.4) |
| Device component issue | 2 (2) | 1 (1) | 1 (0.4) | 0 (0) |
| Device occlusion | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Infusion site erythema | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Infusion site pain | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Infusion site bruising | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Infusion site hemorrhage | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Injection site reaction | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Medical device complication | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) |
| Catheter site edema | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| Catheter site swelling | 3 (3) | 0 (0) | 0 (0) | 0 (0) |
| a | ||||
A literature search of MEDLINE®
| 1 | Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized, multicenter clinical trial. J Clin Oncol. 2016;34(8):786-793. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 |
Would you like to clear and leave your conversation? Message history will be lost.